Aging, Statins and Mitochondrial Mutations


dr_duane_graveline_m.d._134By Duane Graveline, MD, MPH

Abundant research evidence now exists in the medical  literature indicating that diminished mitochondrial function, through excess oxidation, occurs inevitably as we age and is a major factor in fatiguing illnesses.

This is a reflection of progressive loss of efficiency in the electron transport chain. This degradation appears to be naturally associated with the process of aging and is the primary mechanism in the fatigue of many chronic diseases.

One of the most important changes in tissues and cells that occurs during aging and chronic degenerative disease is accumulated oxidative damage due to cellular reactive oxygen species (ROS).

ROS are oxidative and free radical oxygen- and nitrogen-containing molecules, such as nitric oxide, oxygen and hydroxide radicals and other molecules. Critical targets of ROS are the genetic apparatus with its susceptibility to mutations and cellular membranes and in the latter case, oxidation can affect lipid fluidity, permeability and membrane function. Similar changes occur in fatiguing illnesses, such as chronic fatigue syndrome (CFS), where patients show increased susceptibility to oxidative stress. 

The major consequence of excess oxidation is excess mitochondrial damage. Not only is the rate of damage increased as we age but our ability to identify and replace mitochondrial DNA defects degrades.

Another important change caused by accumulated ROS damage during aging and in fatigue is loss of electron transport function, and this appears to be directly related to mitochondrial membrane lipid oxidative change, which can induce permeability changes in mitochondria and loss of transmembrane potential and oxidative phosphorylation. 

A major contributor to this excess accumulation of oxidative damage is Coenzyme Q10 deficiency, the principle anti-oxidant to mitochondrial function. Our ability to synthesize CoQ10 progressively falls with age and by midlife, most of us are completely dependent on external sources of this vital substance.

It is difficult to overstate the importance of this powerful anti-oxidant for in addition to its role as suppressor of ROS accumulation, it also is vital for cell wall integrity and is a necessary element of our electron transport system.

Every cell in the human body requires energy in the form of adenosine triphosphate, or ATP.  No CoQ10 – no ATP, says it all. Few, if any, seniors have the CoQ10 adequacy of when they were 30. Supplementation is not only important for this group but critical for most.

The use of statin drugs greatly enhances this problem by two mechanisms. The first is by the inevitable inhibition of CoQ10 synthesis by this class of drugs. This is what reductase inhibitors do! To reduce cholesterol, statin drugs block the mevalonate pathway, critical to the synthesis of such vital substances as CoQ10 and dolichol.


You have heard the term collateral damage? Collateral damage is when unintended injury occurs, incidentally, while going after a specific target. In their priority to reduce cholesterol, the drug companies accepted this loss of other critical elements of our mevalonate pathway as collateral damage. Is it any wonder we have seen so many side effects?

Dolichols are critical to the synthesis of  glycoproteins. Their importance is difficult to overstate. Made in the endoplasmic reticulum in every cell in the body, glycoproteins comprise the neuropeptide molecules of emotion, our cell identification molecules, cell communication molecules and they are vital to immunodefense.

Our ability to synthesize dolichols progressively falls off with time in many people due to genetic predisposition, nutritional factors and prior disease. So many in midlife are not all that different from statin users in that dolichol insufficiency may be present.

This is another reason why from midlife on, strange things begin to happen in our bodies, all of them bad. It is also why statin users and seniors are all in the same boat regarding mitochondrial mutations.

Merck first developed the statin drug, lovastatin, back in the late eighties. This drug’s brand name was Mevacor®. In 1990, the U.S. Patent Office granted Merck two patents for the use of CoQ10 with its new statin because in its original patent request, Merck cited concerns about the inflammation to come from statin use if CoQ10 were not used concomitantly. This is documented.

Once having received the patents, Merck simply shelved them and proceeded to market Mevacor, never cautioning the medical community about their concerns regarding statin inflammation.

Now, on the basis of thousands of damage reports from statin victims, many in the medical profession now estimate that some 60% of side effects could have been prevented by the concurrent use of CoQ10.

Duane Graveline MD MPH
Former USAF Flight Surgeon
Former NASA Astronaut
Retired Family Doctor

Updated December 2015
 

Books From Amazon

The Statin Damage Crisis
Cholesterol is Not the Culprit
Statin Drugs Side Effects
Lipitor, Thief of Memory


Over 12,000 reader posts:

spacedoc Forum